Banco Bilbao Vizcaya Argentaria S.A. Has $29.60 Million Stock Holdings in Bristol Myers Squibb Company $BMY

Banco Bilbao Vizcaya Argentaria S.A. raised its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 2.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 656,339 shares of the biopharmaceutical company’s stock after buying an additional 18,244 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Bristol Myers Squibb were worth $29,595,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in BMY. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $25,000. Harbor Capital Advisors Inc. increased its position in Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 313 shares during the period. Total Investment Management Inc. bought a new position in Bristol Myers Squibb during the second quarter worth $38,000. Twin Peaks Wealth Advisors LLC acquired a new position in Bristol Myers Squibb during the 2nd quarter valued at $40,000. Finally, Bank of Jackson Hole Trust boosted its holdings in Bristol Myers Squibb by 352.2% in the 3rd quarter. Bank of Jackson Hole Trust now owns 1,040 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 810 shares during the period. 76.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on BMY. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their price target for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. Morgan Stanley reiterated an “underweight” rating and issued a $40.00 target price on shares of Bristol Myers Squibb in a research note on Friday, February 6th. UBS Group reissued a “buy” rating and set a $70.00 target price on shares of Bristol Myers Squibb in a research report on Friday, March 6th. Barclays initiated coverage on Bristol Myers Squibb in a report on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price target for the company. Finally, Citigroup raised their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Nine equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $61.00.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $59.02 on Friday. The firm has a market cap of $120.18 billion, a P/E ratio of 17.11, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. The firm’s 50-day simple moving average is $58.24 and its 200-day simple moving average is $51.43. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). The business had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same period last year, the company earned $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.